Slingshot members are tracking this event:

GlycoMimetics Releases Initial Clinical Data from Phase 1 GMI-1271 Study of Patients with Acute Myeloid Leukemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data GlycoMimetics announced initial phase 1 clinical data that of 13 evaluable patients, 8 (62%) showed clinical response to the treatment.  "Of the eight objective responses, seven patients achieved a complete response (CR), with the eighth patient achieving complete response but with an incomplete blood count recovery (CRi)."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 02, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Initial Phase 1 Clinical Data, Gmi-1271, Acute Myeloid Leukemia